Skip to main content
. Author manuscript; available in PMC: 2013 Nov 26.
Published in final edited form as: Vaccine. 2012 Oct 2;30(50):7265–7270. doi: 10.1016/j.vaccine.2012.09.058

Fig. 2.

Fig. 2

Ad5 vector-induced immune responses. PBMC and sera were isolated from vaccinated and vector control RM at baseline (day 0) and during the course of 4 immunizations (A). Ad5 NAb endpoint titers peaked 2 weeks (day 14) after the first injection with either Ad5 [E1-, E2b-]-null (black circle) or multivalent Ad5 [E1-, E2b-]-SIV-gag/pol/nef/env (white square). Thereafter, Ad5 NAb levels decreased to newly established but higher baseline levels. Error bars indicate ± SEM. B. Ad5 CMI responses peaked on day 14 in vector control animals (black circle) and day 28 in Ad5 [E1-, E2b-]-SIV immunized RM. These responses were significantly higher in the vaccinated RM on the first day of Ad5 [E1-, E2b-]-gag/pol/nef/env immunization. *Days that there was a significant difference between the vaccinated and vector control RM (P<0.05).

HHS Vulnerability Disclosure